| Prev Close | 77.54 |
| Open | 76.75 |
| Day Low/High | 76.20 / 77.53 |
| 52 Wk Low/High | 60.89 / 85.97 |
| Volume | 8.56M |
| Avg Volume | 21.89M |
Gilead Sciences Inc. (GILD)
76.58
0.96
1.20
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 1.25B |
| Market Cap | 93.30B |
| EPS | 4.20 |
| P/E Ratio | 19.08 |
| Div & Yield | 2.72 (3.51%) |
Gilead Has Become and Will Be a Volatile Name
I would consider any entry a trade, and not an investment.
Shares of Gilead Could Surge to the $88 Area in the Near-Term
Any modest intraday dip is probably a buying opportunity.
There's Now Reason, and Science, to Playing GILD
Here's what the charts say about entering Gilead Sciences.
Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout
Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.
This Drugmaking Dividend Stock Due for Shot in the Arm
Gilead offers a nearly 4% yield and looks ready to return to growth.
Target the Bullish Pattern in Gilead Sciences
Also, another buy setup is emerging in Nutanix.
Alibaba, Salesforce, Constellation Software Make RBC's List of Top 2020 Picks
RBC analysts expect Alibaba and Salesforce to continue posting strong double-digit sales growth, and remain fans of Constellation's M&A-driven growth strategy.
3 Biotech Stocks With the Best-Looking Charts
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
Markets Looking Good
"Politics: "Poli" a Latin word meaning "many" and "tics" meaning "bloodsucking creatures" - Robin Williams Markets are looking good a half hour into the trading day. All the major indices are nicely in the black with the NASDAQ up approximately one ...
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
One Prescription for Uncertain Market? Gilead Sciences
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
I'm Looking at Gilead and Merck for Buy Entry Positions
Let's see if either of these names provide an entry this week.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
3 Autopilot Funds for a High-Yield Portfolio
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Gilead Sciences Is Regaining Its Shine
Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Seattle Genetics Struggles as Other Biotech Stocks Rise
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
Inverted Yield Curve Has Lost a Lot of Its Predictive Power
The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...
Before the Open
Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...
The Real Money Post Industrial Average Continues to Soar
The RMPIA rose 10.5% during the first half of the current quarter.
I Like These 2 Smaller Name Biotech Stocks
I still believe it will be a big year for buyouts across the biotech industry.
